Skip to Content
Søk Menu

Nye behandlingstilbud for HER2-lav brystkreft

Bjørn Naume, professor ved Oslo Universitetssykehus, overlege og leder for Norsk brystkreftgruppe, forklarer i denne MEDtalken om de tilgjengelige behandlingsalternativene for HER2-lav brystkreft i Norge. Han har hovedfokus på behandling med trastuzumab deruxtecan, som er undersøkt i DESTINY-Breast04 studien.
Bjørn Naume

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Nordic Collaboration on Breast Cancer Research Reignited

/ BestPractice Nordic
Brystkreft
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
BrystkreftESMO24 Play the Video 04:50
Bjørn Naume

Flere behandlingsmuligheter nå enn før for HER2-lav brystkreft

/ Bjørn Naume
Brystkreft Play the Video 1:40
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BrystkreftESMO24 Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
BrystkreftESMO24 Play the Video 1:23

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
BrystkreftESMO24

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
BrystkreftESMO24

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystkreft

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystkreft
Back to top